Results 141 to 150 of about 27,935 (169)

Model‐based approach to dose optimization of lopinavir/ritonavir when co‐administered with rifampicin

British Journal of Clinical Pharmacology, 2012
Paolo Denti, Helen Mcilleron, Ulrika Simonsson   +2 more
exaly  

Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients

Journal of Antimicrobial Chemotherapy, 2020
Etienne De Montmollin, Quentin Le Hingrat, Paul-Henri Wicky   +2 more
exaly  

Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells

Molecules, 2018
Yousef Al-Abed, Dijana Bovan, Sanja Mijatović   +2 more
exaly  

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet, The, 2020
Edmund Juszczak, Lucy Chappell, Martin Landray   +2 more
exaly  

Lopinavir

2017
openaire   +1 more source

COMPOSITIONS OF LOPINAVIR

2013
GIARDIELLO MARCO NORMAN, MCDONALD THOMAS OLIVER, OWEN ANDREW, RANNARD STEVEN PAUL, LONG JAMES, MARTIN PHILIP JOHN, SMITH DARREN LEE   +6 more
openaire   +3 more sources

Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine

Journal of Clinical Pharmacology, 2006
Pearl Campbell, Bill Cameron
exaly  

Lopinavir

2007
openaire   +1 more source

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir

British Journal of Pharmacology, 2010
A H Schinkel, A D R Huitema
exaly  

Lopinavir.

2011
openaire   +1 more source